This study will provide highly reliable information about the use of tight blood glucose control in critically ill patients. It involves an international collaboration between opinion leaders in this field and uses sophisticated statistical methods to combine data from all the clinical trials in this area. The study will clarify many of the current clinical questions about tight glucose control during critical illness, informing practice guidelines in Australia and around the world.
Patient Safety And Therapeutic Implications Of A New Glucose Lowering Agent For Type 2 Diabetes And High Blood Glucose States In The Critically Ill
Funder
National Health and Medical Research Council
Funding Amount
$88,193.00
Summary
Dr Mark Plummer is a young intensive care trainee and scientist whose research activities are clinically based and relate primarily to the therapeutic implications of novel blood glucose lowering agents in diabetes and critical illness. He also has an interest into the effects of critical illness on upper gastrointestinal function. The results of these studies are expected to lead to safer drug regimens to control high blood sugar levels for diabetics in the community as well as in the intensive ....Dr Mark Plummer is a young intensive care trainee and scientist whose research activities are clinically based and relate primarily to the therapeutic implications of novel blood glucose lowering agents in diabetes and critical illness. He also has an interest into the effects of critical illness on upper gastrointestinal function. The results of these studies are expected to lead to safer drug regimens to control high blood sugar levels for diabetics in the community as well as in the intensive care unit.Read moreRead less